 price
train run time track work
thesi updat chalk anoth
ep beat rais drew solid perform
across busi ex-pharmedium lash
known track even adjust one-tim item
quarter execut year street estim
like move higher partial explain better
ytd perform vs howev potenti chang
drug price dc even though comprehens rebat
chang look tabl opioid litig
continu drug store financi troubl keep us sidelin
manag perform abli macro factor
like weigh valuat expect strateg action
less like thu rais estim
continu oper perform maintain line
tax
bn bn
share lower mm mm
work assumpt
brand gener
in-lin
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
strong perform continu
tend lower contribut period
opex tend higher
expect sg favor continu
provid guidanc call
pharmedium progress plan
middl parti audit open facil
part work plan reopen memphi
mwi benefit solid demand particularli companion anim
work gain cost effici technolog
new custom win sale exist custom
releas report next month respond crisi
sg benefit lower healthcar cost quarter
interest incom quarter higher rates/invest cash balanc
lash continu transit year management excit long term
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk potenti resumpt independ price war result materi margin degrad
signific profit pressur signific downtick sell-sid gener deflat without similar movement buy side margin
result overal compress increment soft pharmedium growth lessen inflat continu challeng
relat revamp qc process polit threat chang rx price methodolog gross net intens scrutini
opioid curtail distribut profit execut challeng onboard hd smith asset potenti leakag key
independ custom transit period inabl transit specialti contract long term new econom
allow fair payment differenti servic
laboratori corp america
articl articl
time dissemin august
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
